TrialTargeted oncology2014

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Nicolas Penel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.